BACKGROUND:Metabolic syndrome (MetS) and increased inflammatory markers, both predictors of future cardiovascular events, are more prevalent in women with coronary heart disease (CHD). The influence of cardiac rehabilitation (CR) on MetS and inflammatory biomarkers is not well characterized for women. PURPOSE: : The purpose of this article was to examine the effects of a 12-week behaviorally enhanced CR exclusively for women compared with traditional CR on components of the MetS and inflammatory markers in women with CHD. METHODS: The randomized clinical trial used 2 treatment groups, both receiving a comprehensive 12-week CR program, with 1 group receiving a motivationally enhanced intervention exclusively for women. A subset of 91 women (mean age, 61.6 years) from the parent study provided serum samples to examine the effects of CR on high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1). RESULTS: After CR, the total sample of women demonstrated significant reductions in hsCRP (P =.002), IL-6 (P <.001), TNF-alpha (P =.010), and ICAM-1 (P =.016). Women in the gender-tailored CR program significantly improved all biomarker levels compared with baseline (P <.05 for all), whereas those in the traditional group improved only hsCRP (P <.05) and IL-6 (P <.05) levels. The combined study group demonstrated improvements in several components of MetS (triglycerides, waist circumference, and systolic blood pressure) but not in others (high-density lipoprotein cholesterol, fasting glucose, and diastolic blood pressure). CONCLUSION:Cardiac rehabilitation promotes greater improvements in inflammatory biomarkers than in components of MetS for women with CHD. Improvements in body composition or weight may not be a precondition for the benefits of exercise because of loss of abdominal fat. Examining components of MetS as continuous variables is recommended to prevent lost information inherent in dichotomization.
RCT Entities:
BACKGROUND:Metabolic syndrome (MetS) and increased inflammatory markers, both predictors of future cardiovascular events, are more prevalent in women with coronary heart disease (CHD). The influence of cardiac rehabilitation (CR) on MetS and inflammatory biomarkers is not well characterized for women. PURPOSE: : The purpose of this article was to examine the effects of a 12-week behaviorally enhanced CR exclusively for women compared with traditional CR on components of the MetS and inflammatory markers in women with CHD. METHODS: The randomized clinical trial used 2 treatment groups, both receiving a comprehensive 12-week CR program, with 1 group receiving a motivationally enhanced intervention exclusively for women. A subset of 91 women (mean age, 61.6 years) from the parent study provided serum samples to examine the effects of CR on high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1). RESULTS: After CR, the total sample of women demonstrated significant reductions in hsCRP (P =.002), IL-6 (P <.001), TNF-alpha (P =.010), and ICAM-1 (P =.016). Women in the gender-tailored CR program significantly improved all biomarker levels compared with baseline (P <.05 for all), whereas those in the traditional group improved only hsCRP (P <.05) and IL-6 (P <.05) levels. The combined study group demonstrated improvements in several components of MetS (triglycerides, waist circumference, and systolic blood pressure) but not in others (high-density lipoprotein cholesterol, fasting glucose, and diastolic blood pressure). CONCLUSION: Cardiac rehabilitation promotes greater improvements in inflammatory biomarkers than in components of MetS for women with CHD. Improvements in body composition or weight may not be a precondition for the benefits of exercise because of loss of abdominal fat. Examining components of MetS as continuous variables is recommended to prevent lost information inherent in dichotomization.
Authors: Christine Espinola-Klein; Hans J Rupprecht; Christoph Bickel; Karl Lackner; Renate Schnabel; Thomas Munzel; Stefan Blankenberg Journal: Atherosclerosis Date: 2007-03-02 Impact factor: 5.162
Authors: Theresa M Beckie; Gerald F Fletcher; Jason W Beckstead; Douglas D Schocken; Mary E Evans Journal: J Cardiopulm Rehabil Prev Date: 2008 Jan-Feb Impact factor: 2.081
Authors: Vasilios G Athyros; Anna I Kakafika; Asterios Karagiannis; Dimitri P Mikhailidis Journal: Atherosclerosis Date: 2008-03-06 Impact factor: 5.162
Authors: Eric Yan; Steve Chen; Kurt Hong; Woo Sung Kim; Anita Bajpai; Leo Treyzon; Luigi Gratton; Robert Elashoff; He-Jing Wang; Zhaoping Li; David Heber Journal: Metab Syndr Relat Disord Date: 2008-03 Impact factor: 1.894
Authors: Tobias Pischon; Frank B Hu; Kathryn M Rexrode; Cynthia J Girman; Joann E Manson; Eric B Rimm Journal: Atherosclerosis Date: 2007-08-02 Impact factor: 5.162
Authors: Theresa M Beckie; Gerald Fletcher; Maureen W Groer; Kevin E Kip; Ming Ji Journal: J Cardiopulm Rehabil Prev Date: 2015 Mar-Apr Impact factor: 2.081
Authors: Dianne M Babbitt; Keith M Diaz; Deborah L Feairheller; Kathleen M Sturgeon; Amanda M Perkins; Praveen Veerabhadrappa; Sheara T Williamson; Jan Kretzschmar; Chenyi Ling; Hojun Lee; Heather Grimm; Sunny R Thakkar; Deborah L Crabbe; Mohammed A Kashem; Michael D Brown Journal: Int J Hypertens Date: 2013-04-18 Impact factor: 2.420